Get the Stockscreener App
0.6666
11.24%
-0.0844
After Hours:
.74
0.0734
+11.01%
Passage Bio Inc stock is traded at $0.6666, with a volume of 395.45K.
It is down -11.24% in the last 24 hours and up +10.47% over the past month.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease.
See More
Previous Close:
$0.751
Open:
$0.788
24h Volume:
395.45K
Relative Volume:
1.46
Market Cap:
$43.55M
Revenue:
-
Net Income/Loss:
$-68.80M
P/E Ratio:
-0.3252
EPS:
-2.05
Net Cash Flow:
$-59.06M
1W Performance:
+29.76%
1M Performance:
+10.47%
6M Performance:
-41.01%
1Y Performance:
+7.86%
1-Day Range:
$0.6609
$0.7899
1-Week Range:
$0.4709
$0.7899
52-Week Range:
$0.451
$1.79
Passage Bio Inc Stock (PASG) Company Profile
Name
Passage Bio Inc
Sector
Industry
Phone
(267) 866-0312
Address
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Compare PASG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
0.6666 | 43.55M | 0 | -68.80M | -59.06M | -2.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-08-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-19-22 | Downgrade | Goldman | Buy → Neutral |
| Jul-01-21 | Initiated | Raymond James | Outperform |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Mar-04-21 | Upgrade | Goldman | Neutral → Buy |
| Feb-04-21 | Initiated | Guggenheim | Buy |
| Jan-25-21 | Initiated | Wedbush | Outperform |
| Jan-04-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-11-20 | Initiated | Citigroup | Neutral |
| Aug-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-25-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-25-20 | Initiated | Chardan Capital Markets | Buy |
| Mar-24-20 | Initiated | Cowen | Outperform |
| Mar-24-20 | Initiated | Goldman | Buy |
| Mar-24-20 | Initiated | JP Morgan | Overweight |
View All
Passage Bio Inc Stock (PASG) Latest News
Passage Bio CEO Will Chou to Share Insights at Guggenheim Healthcare Innovation Conference! - MSN
Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateOn November 13, 2024, Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company focusing on innovative therapies for rare cardiopulmonary dise - Defense World
Horizon Space Acquisition I Corp. Approved for Listing on Nasdaq Capital Market - Defense World
Seres Therapeutics Receives Notification from Nasdaq Regarding Bid Price Requirement - Defense World
BioRestorative Therapies Provides Business Update and Financial Results for Q3 2024 - Defense World
Metal Sky Star Acquisition Amends Investment Management Trust Agreement and Extends Business Combination Period - Defense World
Nikola Corporation Enters Material Definitive Agreements, Modifies Convertible Notes – 8-K Filing Highlights - Defense World
AgriFORCE Growing Systems Announces Strategic Shift Towards Sustainable Technology Initiatives - Defense World
Cognition Therapeutics Reports Financial Results for the Third Quarter 2024UNAUDITED – On November 13, 2024, Cognition Therapeutics, Inc. (NASDAQ: CGTX) disclosed its financial results for the third quarter ending September 30, 2024. Within the detai - Defense World
Orange County Bancorp, Inc. (NASDAQ: OBT) Distributes Investor Presentation and Financial Disclosure - Defense World
Digital Brands Group (NASDAQ: DBGI) Announces Strategic Partnership with VaynerCommerce - Defense World
MRC Global Inc. Enters into Fifth Amended and Restated Loan Agreement - Defense World
Air Industries Group to Release Financial Results for Q3 2024 - Defense World
Intevac (NASDAQ: IVAC) Enters into Letter Agreement with Palogic Value Management, L.P.Santa Clara, CA, November 13, 2024 – Intevac, Inc. (NASDAQ: IVAC) disclosed today in a Form 8-K filing that on November 8, 2024, the company entered into a letter - Defense World
Advance Auto Parts Enters Amendment to Credit Agreement - Defense World
Sound Point Meridian Capital, Inc. (NYSE: SPMC) Announces Financial Results for Quarter Ended September 30, 2024 - Defense World
Tetra Tech Reports Record Fiscal 2024 and Fourth Quarter ResultsOn November 13, 2024, Tetra Tech, Inc. (NASDAQ: TTEK) released its financial results for the fourth fiscal quarter and the fiscal year ended September 29, 2024. According to the report - Defense World
Roth CH Acquisition II Files 8-K Report with SEC Detailing Company Updates and Investor Presentation - Defense World
Capricor Therapeutics Announces Financial Results for Third Quarter 2024 and Strategic DevelopmentsSAN DIEGO, November 13, 2024 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR) recently disclosed its financial outcomes for the third - Defense World
Predictive Oncology Inc. Issues Press Release Detailing Financial Results for Q3 2024Predictive Oncology Inc., a leading biopharmaceutical company, released a pivotal press release detailing its financial results for the quarter ending September 30 - Defense World
Flutter Entertainment Announces Launch of Share Repurchase Program - Defense World
374Water Inc. Reports Third Quarter 2024 Results and Business Update - Defense World
Broadwind, Inc. Reports Financial Results for Quarter Ending September 30, 2024 - Defense World
Workhorse Group Reschedules Earnings Call to November 19, 2024 - Defense World
Cabaletta Bio Reports Q3 2024 Financial Results and Clinical Trial Advancements - MyChesCo
Passage Bio stock hits 52-week low at $0.54 amid market challenges - Investing.com India
Layoff Tracker: Sensei to Cut 46% of Workforce, Close Research Site - BioSpace
Passage Bio Advances PBFT02 Gene Therapy Program Amidst Positive Q3 2024 Results - MSN
Vestal Point Capital, LP Increases Stake in Passage Bio Inc - GuruFocus.com
Passage Bio Achieves Milestones in Gene Therapy Trials - Yahoo Finance
Passage Bio Shows Progress in Gene Therapy Trials - TipRanks
PASGPassage Bio, Inc. Latest Stock News & Market Updates - StockTitan
Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights - GlobeNewswire
Passage Bio's Q3 Shows Progress: Clinical Trial Advances, Cash Runway Extended to 2026 | PASG Stock News - StockTitan
Annovis Bio Advances Alzheimer’s Treatment with Phase 3 Trials and Financial Updates - MyChesCo
Cabaletta Bio to Spotlight Groundbreaking Cell Therapies at Guggenheim's Healthcare Innovation Conference! - MyChesCo
Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference - StockTitan
R. Nolan Townsend, Sandi See Tai, MD, and Kim G. Johnson, MD, on Gene Therapy for APOE4 Homozygous Alzheimer Disease - CGTLive™
Data Roundup: October 2024 Features Update for TCR-Based Autologous Cell Therapy in Melanoma, the First Clinical Demonstration of Therapeutic RNA Editing in Humans, and More - CGTLive™
Passage Bio reports advances in gene therapy for dementia - Investing.com
Gene therapy shows promise in frontotemporal dementia study - Investing.com
Gene therapy shows promise in frontotemporal dementia study By Investing.com - Investing.com South Africa
Passage Bio reports advances in gene therapy for dementia By Investing.com - Investing.com South Africa
Passage Bio Presents Preclinical and Interim Clinical Data - GlobeNewswire
Goldman Sachs, Morgan Stanley bullish on BioAge, cite Lilly relationship - MSN
Will Passage Bio See An Uplift? Frontotemporal Dementia Trial Data Holds The Key - RTTNews
PASG stock touches 52-week low at $0.55 amid market challenges - Investing.com
Plexxikon, Inc. - Scrip
Passage Bio Inc [PASG] 10% Owner makes an insider purchase of 39,300 shares worth 27903.0. - Knox Daily
Director Mayson Howard John sale 4,000 shares of Ovintiv Inc [OVV] - Knox Daily
Passage Bio Inc (PASG) Stock: A Year of Highs and Lows - The InvestChronicle
Passage Bio Inc Stock (PASG) Financials Data
Revenue
Net Income
Cash Flow
EPS
Passage Bio Inc Stock (PASG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 10% Owner |
Sep 17 '24 |
Sale |
0.73 |
111,400 |
81,322 |
7,859,500 |
| ORBIMED ADVISORS LLC | 10% Owner |
Sep 16 '24 |
Sale |
0.74 |
63,100 |
46,694 |
7,970,900 |
| ORBIMED ADVISORS LLC | 10% Owner |
Sep 18 '24 |
Sale |
0.73 |
25,631 |
18,711 |
7,833,869 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):